Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
A phase 3 trial of Datopotamab deruxtecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT07291037 by AstraZeneca, with 400 participants planned, started 2025-10-31 and due to reach its primary completion in 2029-01-29. Interventions recorded: Datopotamab deruxtecan (Dato-DXd), Docetaxel. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAssess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral
Shares Docetaxel, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Shares Datopotamab deruxtecan, AstraZeneca, Non-small-cell lung cancer.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel, Non-small-cell lung cancer.